This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The analysis of the LRC-CPPT results was entirely consistent with the hypothesis set forth in the study protocol adopted by the LRC investigators in 1973: "It is postulated that cholesterol reduction with a bile acid sequestrant will produce a significant decrease in the death rate from atherosclerotic coronary heart disease and in the occurrence rate of definite nonfatal myocardial infarction in a group of asymptomatic patients with primary type II hyperlipoproteinemia, also receiving a cholesterol lowering diet, when compared with a diet and placebo treated group." The term "significant" was not defined in terms of a particular statistical probability level.The statement cited by Drs L'Abbeé, Detsky, and Logan was taken from a published description of the procedure for estimating a sample size sufficient to provide the LRC-CPPT with the statistical power to test this hypothesis. The intent of this statement was to explain to the reader the
The Lipid Research Clinics Coronary Primary Prevention Trial-Reply. JAMA. 1985;253(21):3091. doi:10.1001/jama.1985.03350450063009